GNMSF Stock Price, Chart, Stats & News

Genmab A/S, founded in 1999 and based in Copenhagen, Denmark, is a biopharmaceutical firm focused on developing antibody-based therapeutics to treat cancer and a range of other diseases. The company markets several key products, including DARZALEX (daratumumab) for multiple myeloma, teprotumumab for thyroid eye disease, ofatumumab to address chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic gastric, esophageal, and non-small cell lung cancers. Their extensive pipeline includes daratumumab, also being explored for non-MM blood cancers and AL amyloidosis, along with GEN1047, tisotumab vedotin for cervical, ovarian, and other solid cancers, and specialized DuoBody and HexaBody platforms targeting various solid tumors and hematological malignancies, such as Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and CLL.